TAA-specific CD8+ T-cells reinjection strategies used in cancers have been optimized by transgenic T-cell receptor T-cells engineering (tgTCR T-cells), which enables us to recognize TAA specifically presented by selected MHC molecules [152,153,154]. This evidence concerns the gene HLA-C and cancer.